Logo

LAB

Standard BioTools Inc.

LAB

Standard BioTools Inc. • NASDAQ
$1.50 ▲ 4.90% (+0.07)
Market Cap $576.85 M
52w High $2.25
52w Low $0.92
Dividend Yield 0%
P/E -3.85
Volume 1.33M
Outstanding Shares 384.57M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $19.552M ▼ $32.951M ▼ $-34.687M ▼ -177.409% ▼ $-0.091 ▼ $-31.293M ▼
Q2-2025 $21.762M ▼ $36.325M ▼ $-33.459M ▼ -153.75% ▼ $-0.09 ▼ $-14.279M ▲
Q1-2025 $40.795M ▼ $52.711M ▼ $-26.033M ▲ -63.814% ▲ $-0.07 ▲ $-22.011M ▲
Q4-2024 $46.718M ▲ $54.722M ▼ $-34.072M ▼ -72.931% ▼ $-0.09 ▼ $-26.022M ▼
Q3-2024 $44.969M $54.979M $-26.938M -59.903% $-0.07 $-20.44M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $194.903M ▼ $539.636M ▼ $139.977M ▲ $399.659M ▼
Q2-2025 $237.085M ▼ $556.965M ▼ $132.43M ▲ $424.535M ▼
Q1-2025 $258.062M ▼ $579.597M ▼ $125.002M ▼ $454.595M ▼
Q4-2024 $292.874M ▼ $612.344M ▼ $140.622M ▼ $471.722M ▼
Q3-2024 $366.33M $681.539M $192.206M $489.333M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-34.687M ▼ $-22.202M ▼ $-6.681M ▼ $-112K ▼ $-29.198M ▼ $-23.088M ▼
Q2-2025 $-33.459M ▼ $-20.668M ▲ $27.505M ▲ $108K ▲ $7.733M ▲ $-22.555M ▲
Q1-2025 $-26.033M ▲ $-30.283M ▼ $14.625M ▼ $-46K ▲ $-15.347M ▲ $-35.337M ▼
Q4-2024 $-34.072M ▼ $-14.059M ▲ $25.726M ▲ $-54.52M ▼ $-43.12M ▲ $-17.441M ▲
Q3-2024 $-26.938M $-27.869M $-30.883M $-2K $-59.162M $-30.124M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Consumables
Consumables
 $40.00M ▲$10.00M ▼$10.00M ▲$10.00M ▲
Instruments
Instruments
 $20.00M ▲$10.00M ▼$10.00M ▲$10.00M ▲
Product
Product
 $50.00M ▲$20.00M ▼$20.00M ▲$10.00M ▼
Service and Other Revenue
Service and Other Revenue
 $0 ▲$0 ▲$10.00M ▲$10.00M ▲
Collaboration and Other Revenue
Collaboration and Other Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲
Product And Service
Product And Service
 $80.00M ▲$40.00M ▼$0 ▼$0 ▲
Service
Service
 $40.00M ▲$20.00M ▼$0 ▼$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been slowly improving over the last few years, and gross profit has generally moved in the right direction, which suggests the core products are gaining some traction. However, the company still runs at a sizeable operating loss, and those losses actually widened most recently versus the prior year. Net losses remain meaningful, even if they look better than the worst year in the period. Overall, the income statement describes a business that is growing its top line but has not yet proven it can cover its full cost base or deliver consistent profitability.

Balance Sheet

Balance Sheet The balance sheet has strengthened notably in the most recent year, largely thanks to transactions that boosted total assets, cash, and shareholder equity. Debt has come down from prior levels, easing some balance-sheet risk and giving the company more financial flexibility. The result is a capital structure that now looks much more resilient than it did a few years ago, though long-term value still depends on eventually turning those resources into sustainable earnings.

Cash Flow

Cash Flow Operating cash flow has been negative every year, which means the company is still consuming cash to fund its operations. Free cash flow is also consistently negative, though capital spending needs are relatively light. Cash burn increased again most recently compared with the prior year, so the path to self-funding operations is not yet in sight. For now, the business is reliant on its strengthened cash position and external capital moves rather than internally generated cash.

Competitive Edge

Competitive Edge Standard BioTools operates in specialized niches of life science tools, including high-plex proteomics, mass cytometry, and microfluidics. Its platforms are built around proprietary reagents and instruments, often used together in a closed ecosystem, which supports recurring revenue and creates switching costs for customers. Strong intellectual property, highly differentiated measurement capabilities, and partnerships with large pharma and research institutions provide a defensible position. At the same time, the company competes in a dynamic, innovation-driven market with technically advanced rivals, so maintaining this edge will require ongoing execution and customer adoption.

Innovation and R&D

Innovation and R&D The company’s story is heavily driven by innovation. It offers unique technologies such as SOMAmer-based proteomics assays, metal-tagged single-cell cytometry, and microfluidic genomics systems, all aimed at delivering deeper biological insights from limited samples. Management is actively reshaping the portfolio through R&D focus and acquisitions, emphasizing higher-margin, recurring-revenue tools and services. Recent product launches and collaborations point to a strategy of moving closer to translational and clinical research, where performance and regulatory-ready workflows matter. The main question is not whether the technology is novel—it clearly is—but how quickly it can scale commercially and translate into durable, profitable growth.

Summary

Standard BioTools is a life science tools company in the midst of a strategic transformation. On one hand, it has cutting-edge platforms, a stronger balance sheet, and a clearer focus on high-growth proteomics and multi-omics markets supported by patents and a closed ecosystem. On the other hand, the business still generates meaningful operating and net losses and remains cash-flow negative, so financial performance has not yet caught up with the technological promise. Future progress will hinge on converting its innovation and acquisitions into broader adoption, improved margins, and eventually sustainable profitability, all in a competitive and fast-moving market where execution quality will matter as much as scientific strength.

NEWS

November 19, 2025 · 11:30 AM UTC

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Read more

November 10, 2025 · 12:15 PM UTC

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

Read more

November 4, 2025 · 4:05 PM UTC

Standard BioTools Reports Third Quarter 2025 Financial Results

Read more

October 21, 2025 · 7:00 AM UTC

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Read more

September 3, 2025 · 9:15 AM UTC

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

Read more